Cellusion Inc., a regenerative medicine startup aiming to solve the global Corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells (CECSi Cells) for bullous keratopathy novel treatment (PJ code: CLS001), today announced it has completed a 1.1 billion yen fundraising round led by existing investors DBJ Capital, Keio Innovation Initiative, and SMBC Venture Capital and new investors Gemseki, Toho Holding, Toyo Seikan Group Holdings and University of Tokyo Edge Capital Partners. The new round brings Cellusion’s total funding in the past year to 1.7 billion yen

[Use of the Funding]
Cellusion will use the funding to prepare for the company-sponsored phase 1/2 clinical trials of CLS001 in Japan and overseas, enlarge both of its Tokyo-based research and business teams, and proceed with R&D activities of other pipelines. In addition, by promoting business cooperation with Toho Holdings, Japan-based pharmaceutical wholesaler, and Toyo Seikan Group Holdings, a Japanese multinational conglomerate packaging materials manufacturer, to build the supply chain of CLS001. Cellusion will enhance its efforts to deliver CLS001 for bullous keratopathy patients all over the world.